FacebookTwitterGoogle+RedditEmail

Medical Hemp

Project CBD has just sent out its introductory pitch to California dispensaries. “ProjectCBD.org is the medical marijuana movement living up to its name,” explains outreach coordinator Sarah Russo, optimistically, as she asks the dispensaries to participate in a “collective research effort.” But what are the chances that the dispensary owners, intent on building their own brands, will support a venture aimed at advancing the movement as a whole?

CBD, in case you’re just joining us, is Cannabidiol —a component of the Cannabis plant known to have anti-inflammatory, anti-tumor and other beneficial medical effects. CBD is not psychoactive and actually counters the psychoactive effects of THC. It is the predominant cannabinoid in hemp —plants grown to produce fiber or growing wild. CBD levels go down and THC levels go up when plants are bred to maximize psychoactive effect, as they have been in the U.S. for many generations of plants and people.

It was widely assumed for a long time that CBD had been almost entirely bred out of the Cannabis being grown in California for medical/commercial purposes. And because no analytic chemistry labs were testing Cannabis samples before the winter of 2008-09, there was no way to assess cannabinoid content. Overseas things were different. For many years researchers have been exploring the medical potential of CBD, and G.W. Pharmaceuticals conducted successful clinical trials and got U.K. government approval to market Sativex, a whole-plant extract with equal amounts of CBD and THC, for use by MS patients. Canada and Spain have also issued approvals for Sativex.

The situation in California changed in 2008 when Steve DeAngelo arranged for a lab to test the Cannabis he was providing at Oakland’s Harborside Health Center. DeAngelo had to fund a start-up to accomplish this. When Harborside opened in 2006 he had phoned every analytic lab in the Bay Area and been turned down when he mentioned the C word. In the spring of ’08 he decided to back two entrepreneurs who were launching a lab —the aptly named “Steep Hill”— and to supply them with a large, steady stream of samples to test for mold and cannabinoid content (THC, CBD and CBN, a breakdown product indicative of freshness). At least eight more labs have started testing Cannabis in California since then, and there are labs in Montana and Colorado. ProjectCBD’s Russo says, “We seem to hear from a new lab every week.”

It turns out that CBD is not all that rare —about one in every 600 samples tested by the labs is found to be high in CBD. Evidently, that’s the rate at which a mutation occurs resulting in an excess of the enzyme that transforms a precursor molecule of CBD and THC into one or the other. More than 25 CBD-rich strains have been identified, and Russo says, “We seem to hear about a new strain every week, too.”

The prospect of CBD-rich cannabis becoming available prompted the Society of Cannabis Clinicians to plan a data collection effort. Jeffrey Hergenrather, MD, President of the SCC, had spent years listening to talks about CBD at meetings of the International Cannabinoid Research Society, wishing he could observe its effects on real patients. Hergenrather and co-worker Stacey Kerr, MD have now drafted a survey aimed at documenting patients’ answers to some basic questions about the effects of CBD-rich Cannabis. (For purposes of data collection, “CBD-rich” has been defined as 4% or more CBD, regardless of THC content. The amount of CBD that a given strain contains isn’t the only factor influencing the effects it will exert when ingested. The ratio of CBD to THC may be as or more important. Terpenoid and flavonoid content also appear to be very important.)

Project CBD was launched to publicize and promote the SCC survey(s). Martin A. Lee, the author of Acid Dreams, had been writing about CBD for O’Shaughnessy’s and convinced your correspondent that its re(introduction) into the grassroots supply was going to be a huge, ongoing story and would warrant its own journal of sorts. Over the past year we put a lot of effort into encouraging production by plant breeders and growers who had strains testing high in CBD. Many dispensary owners have been reluctant to stock CBD-rich strains because their present customers are seeking —or are not adverse to— Cannabis that causes euphoria or sedation. In other words, THC content sells, it’s a sure thing. Why should a dispensary spend money and devote shelf space to a type of Cannabis that most medical users haven’t heard of and whose effects are unproven?

Growers, in turn, have to anticipate the wants of dispensary buyers, and are reluctant to devote valuable garden space to plants for which there is no established market. ?Demand at the dispensary level might not take off until effectiveness is established. Which might not happen until significant numbers of patients have tried CBD-rich Cannabis and taken the SCC survey to report their results. Or, as Martin says, “there could be a tsunami of interest any day now.”

ProjectCBD.org provides the whole story to date and a “CBDiary” noting recent developments. The big news as of March 1: for the first time, a California grower has “stabilized” a CBD-rich strain. Lawrence Ringo of the Southern Humboldt Seed Collective is now offering seeds of “Sour Tsunami” that have a one-in-four chance of containing 10-11% CBD (and 6-7% THC).

Read all about it at http://www.projectcbd.com/CBDiary.html#Mar01.11

FRED GARDNER is the managing editor of O’Shaughnessy’s, the journal of cannabis in clinical practice. His email is fred@plebesite.com.

 

 

 

More articles by:

Fred Gardner is the managing editor of O’Shaughnessy’s. He can be reached at fred@plebesite.com

January 15, 2019
Patrick Cockburn
Refugees Are in the English Channel Because of Western Interventions in the Middle East
Howard Lisnoff
The Faux Political System by the Numbers
Lawrence Davidson
Amos Oz and the Real Israel
John W. Whitehead
Beware the Emergency State
John Laforge
Loudmouths against Nuclear Lawlessness
Myles Hoenig
Labor in the Age of Trump
Jeff Cohen
Mainstream Media Bias on 2020 Democratic Race Already in High Gear
Dean Baker
Will Paying for Kidneys Reduce the Transplant Wait List?
George Ochenski
Trump’s Wall and the Montana Senate’s Theater of the Absurd
Binoy Kampmark
Dances of Disinformation: the Partisan Politics of the Integrity Initiative
Glenn Sacks
On the Picket Lines: Los Angeles Teachers Go On Strike for First Time in 30 Years
Jonah Raskin
Love in a Cold War Climate
Andrew Stewart
The Green New Deal Must be Centered on African American and Indigenous Workers to Differentiate Itself From the Democratic Party
January 14, 2019
Kenn Orphan
The Tears of Justin Trudeau
Julia Stein
California Needs a 10-Year Green New Deal
Dean Baker
Declining Birth Rates: Is the US in Danger of Running Out of People?
Robert Fisk
The US Media has Lost One of Its Sanest Voices on Military Matters
Vijay Prashad
5.5 Million Women Build Their Wall
Nicky Reid
Lessons From Rojava
Ted Rall
Here is the Progressive Agenda
Robert Koehler
A Green Future is One Without War
Gary Leupp
The Chickens Come Home to Roost….in Northern Syria
Glenn Sacks
LA Teachers’ Strike: “The Country Is Watching”
Sam Gordon
Who Are Northern Ireland’s Democratic Unionists?
Weekend Edition
January 11, 2019
Friday - Sunday
Richard Moser
Neoliberalism: Free Market Fundamentalism or Corporate Power?
Paul Street
Bordering on Fascism: Scholars Reflect on Dangerous Times
Joseph Majerle III – Matthew Stevenson
Who or What Brought Down Dag Hammarskjöld?
Jeffrey St. Clair - Joshua Frank
How Tre Arrow Became America’s Most Wanted Environmental “Terrorist”
Andrew Levine
Dealbreakers: The Democrats, Trump and His Wall
Jeffrey St. Clair
Roaming Charges: Que Syria, Syria
Dave Lindorff
A Potentially Tectonic Event Shakes up the Mumia Abu-Jamal Case
Nick Pemberton
There Are More Important Things Than The Truth
Brian Cloughley
How Trump’s Insults and Lies are Harming America
David Rosen
Sexual Predators in the Era of Trump
Tamara Pearson
Everything the Western Mainstream Media Outlets Get Wrong When Covering Poor Countries
Richard E. Rubenstein
Trump vs. the Anti-Trumps: It’s the System That Needs Changing Not Just the Personnel
Christopher Ketcham
A Walk in the Woods, Away from the Screens
Basav Sen
Democrats Failed Their First Big Test on Climate
Lauren Smith
Nicaragua – The Irony of the NICA Act Being Signed into Law by Trump
Joseph Natoli
Will Trumpism Outlive Trump?
Olivia Alperstein
The EPA Rule Change That Could Kill Thousands
Medea Benjamin – Alice Slater
The New Congress Needs to Create a Green Planet at Peace
Caoimhghin Ó Croidheáin
Cuba: Trump Turns the Vise
Ramzy Baroud
When Bolsonaro and Netanyahu Are ‘Brothers’: Why Brazil Should Shun the Israeli Model
Mitchell Zimmerman
Government by Extortion
FacebookTwitterGoogle+RedditEmail